OptimizeRx Corp (OPRX) as of March 31, 2026 presents a constrained but not deeply negative liquidation posture at the equity level, driven primarily by the interplay between a meaningful cash/AR base and a debt stack that is larger than most of the tangible asset pool. Under liquidation-lens assumptions: cash and cash equivalents of $20.2M receive full credit; accounts receivable (gross approximately $32-33M implied by the $5.8M cash inflow from AR reduction in Q1 and the prior-period balance of $38.2M at Dec 31, 2024, though the Mar 31, 2026 balance is not separately disclosed in the truncated filing body — filing does not separately tag AccountsReceivableNetCurrent for the current period in the XBRL context provided) recovered at 90-95% contributes meaningful value. Against these liquid assets sits the term loan principal of $23.6M, which must be repaid at face value. Finite-lived intangible assets of $39.8M net carrying value receive a 0% liquidation recovery; goodwill (from Medicx Health 2023, EvinceMed 2022, RMDY Health 2019, CareSpeak 2018 acquisitions) is similarly zeroed — the filing does not separately disclose the goodwill balance in the XBRL tags provided, but it is referenced in narrative. PP&E is de minimis given the asset-light SaaS/platform model. The operating lease liability is immaterial at $373K total with a 2.0-year weighted average term. The most structurally significant liability-side item beyond the term loan is the partner commitment obligation: $31.3M in minimum future payments to channel partners (2026 remainder through 2030), of which $11.4M is due in the remainder of 2026 and $13.6M in 2027. These production commitments do not extinguish on windup and must be carried at face under the liquidation lens, materially expanding the effective liability stack. A post-period-end debt refinancing (May 7, 2026) replaced the $23.6M term loan (12.4% stated, 19.5% effective rate) with a new $25M term loan at SOFR plus 1.75-2.5% plus a $10M revolving facility — this substantially reduces interest burden going forward but does not change the March 31 balance sheet analysis. The net change vs. the prior filing (Dec 31, 2025 10-K) is a modest improvement: total debt fell from $26.3M to $23.6M through a $2.69M principal repayment (including $2.19M excess cash flow sweep), and the current ratio improved from 3.0x to 5.4x reflecting seasonal AR collection. The MFFAIS-reported CLV of negative $20.0M and LLV/OLV of positive $17.8M are directionally consistent with this analysis — the gap reflects goodwill and intangible zeroing under CLV versus the liquid asset value under LLV. A residual material weakness in internal controls over third-party data completeness remains unremediated as of the filing date, introducing some data quality risk to reported AR and revenue figures.
▼ Community Notes